Intensive Adverse Drug Reaction Monitoring Program Improves Detection of Phenytoin-Induced Adverse Drug Reactions
Open Access
- 1 March 2026
- journal article
- research article
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 20, 1-12
Abstract
Purpose: To compare the outcomes of routine versus intensive adverse drug reaction (ADR) monitoring programs among adult in-patients initially treated with phenytoin, and to identify risk factors associated with severe cutaneous adverse reactions (SCARs). Patients and Methods: This retrospective cohort study recruited phenytoin-naïve patients treated at a general hospital in Northern Thailand. Potentially eligible admissions were identified through the electronic medical record by extracting all medication orders for phenytoin during October 2018 to May 2021. Patients were consecutively enrolled and divided into routine adverse drug reaction monitoring (n = 500, rADRM) and intensive adverse drug reaction monitoring (n = 500, iADRM) allocated based on ward-based monitoring models. All participants received standard counseling regarding phenytoin dosing and administration. The rADRM group underwent ADR monitoring during routine follow-up visits, while the iADRM group received additional individualized instruction on ADR recognition and access to a direct pharmacist contact for reporting suspected ADRs. Multivariable logistic regression was performed to identify independent risk factors for SCARs. Results: Patients in the intensive adverse drug reaction monitoring group had a significantly higher detection rate of phenytoin-induced ADRs compared with those in the routine adverse drug reaction monitoring group (OR 2.301, 95% CI 1.091:4.853, p = 0.029), as well as a greater patient-initiated reporting (OR 4.527, 95% CI 2.274:9.010, p < 0.001). Type B ADRs occurred in 3.6% of patients, with the iADRM group documenting more SCARs (36.84% vs. 5.88%, p = 0.044). Discontinuation of phenytoin and prolonged hospitalization were observed in both groups (42.1 vs. 52.9%, p = 0.045). Multivariable logistic regression identified iADRM (OR 13.304, 95% CI 1.183– 149.581, p = 0.036), comorbidities (OR 12.935, 95%Cl 1.514:110.48, p =0.019), omeprazole use (OR 57.112, 95%Cl 9.569:340.875, p < 0.001), and increased age (OR 0.940, 95%Cl 0.893:0.989, p =0.023) as significant risk factors associated with SCARs. Conclusion: Intensive ADR monitoring facilitates earlier detection and reporting of phenytoin-associated ADRs including SCARs. Comorbidities, concomitant omeprazole use, and older age were associated with SCARs. Intensive monitoring programs may enhance patient engagement and improve medication safety by enabling timely recognition and management of adverse reactions.Keywords
This publication has 28 references indexed in Scilit:
- Severe cutaneous adverse reactions in Asians: Trends observed in culprit anti-seizure medicines using VigiBase®Seizure: European Journal of Epilepsy, 2021
- Phenytoin – An anti-seizure drug: Overview of its chemistry, pharmacology and toxicologyFood and Chemical Toxicology, 2020
- Genetic and clinical risk factors associated with phenytoin‐induced cutaneous adverse drug reactions in Thai populationPharmacoepidemiology and Drug Safety, 2020
- Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 UpdateTherapeutic Drug Monitoring, 2018
- HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in East AsiansClinical Pharmacology & Therapeutics, 2018
- Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactionsEuropean Journal of Clinical Pharmacology, 2017
- Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai populationPharmacogenetics and Genomics, 2016
- An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methodsJournal of Clinical Epidemiology, 1995
- THE IMPACT OF CONFOUNDER SELECTION CRITERIA ON EFFECT ESTIMATIONAmerican Journal of Epidemiology, 1989
- Oral phenytoin pharmacokinetics during omeprazole therapy.British Journal of Clinical Pharmacology, 1987